{"name":"Rasim Gucalp","slug":"rasim-gucalp","ticker":"","exchange":"","domain":"","description":"Rasim Gucalp is a biopharmaceutical company with a focus on developing innovative treatments in oncology. The company has one discontinued drug, PS-341 (Velcade-drug), and is currently not providing detailed financial or operational data.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBYRmJ0T0lUMUVhOWJBRElpWmpveGhjU1JVQXF6RTk0ZkY2dVlMNUVQdmVFNlRRU0Y2eWtMTGh4ZVBQblZZODNtYUNya3N4WEpzNFZoNUN3eW5xZDYwNEdR?oc=5","date":"2026-01-27","type":"pipeline","source":"Nature","summary":"Treatment adherence and clinical outcomes of osimertinib in minority patients with advanced EGFR mutated NSCLC - Nature","headline":"Treatment adherence and clinical outcomes of osimertinib in minority patients with advanced EGFR mutated NSCLC","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}